Advertisement

Modern Rheumatology

, Volume 22, Issue 4, pp 491–497 | Cite as

Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan

  • Shumpei YokotaEmail author
  • Tomoyuki Imagawa
  • Takuji Murata
  • Minako Tomiita
  • Yasuhiko Itoh
  • Satoshi Fujikawa
  • Syuji Takei
  • Masaaki Mori
Review Article
  • 197 Downloads

Abstract

Adalimumab is a monoclonal antibody produced by DNA recombination technology, and is the first human monoclonal antibody against human tumor necrosis factor (TNF)-α in the world. Adalimumab binds with high affinity and specificity to soluble TNF-α and normalizes its biological action. The clinical development of adalimumab started in Europe. Adalimumab was approved for the treatment of rheumatoid arthritis (RA) in December 2002 in the United States and in September 2003 in the European Union. Since then, adalimumab has been approved for the expanded indications of psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), psoriasis (Ps), and juvenile idiopathic arthritis (JIA) in the United States and the European Union, and it is now used widely for the treatment of these diseases. In Japan, adalimumab was approved for the treatment of RA in April 2008, and its use was approved for the indications of Ps and PsA in January 2010, and for CD and AS in October 2010. In Japan, children who have been diagnosed and treated according to the “Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007)” (published in this journal in 2007; see reference 1 in the main text), but who have responded poorly to treatment must move onto the next stage of treatment. Such treatments include biological drugs, which, however, should be used with strict adherence to the indications and exclusion criteria and should be used, for the time being, only by physicians trained in how to use them. In Japan, adalimumab was approved for the treatment of JIA in July 2011. Although this drug has brought about a revolutionary advance in the treatment of JIA, it is our task to maximize its therapeutic effects and minimize its toxic effects. The guidance presented here define the indications, exclusion criteria, usage, and evaluation criteria of adalimumab for the treatment of polyarticular JIA.

Keywords

Juvenile idiopathic arthritis Anti-TNF-α monoclonal antibody (adalimumab) Methotrexate Steroids 

Notes

Acknowledgments

The Pediatric Standing Committee of the Japan College of Rheumatology, in collaboration with the Pediatric Rheumatology Association of Japan, produced these guidance on the use of adalimumab for polyarticular juvenile idiopathic arthritis in Japan. The Japanese version of this work was published as a report from the Subcommittee for Juvenile Idiopathic Arthritis of the Japan Pediatric Society.

Conflict of interest

None.

References

  1. 1.
    Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Mod Rheumatol. 2007;17:353–63.PubMedCrossRefGoogle Scholar
  2. 2.
    van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508–16.PubMedCrossRefGoogle Scholar
  3. 3.
    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.PubMedGoogle Scholar
  5. 5.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Miyasaka N. The CHANGE Study Investigator. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04–688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37:299–310.PubMedCrossRefGoogle Scholar
  9. 9.
    Cassidy JT. Chronic arthritis, poly arthritis, oligoarthritis, systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Linsley CB, editors. Textbook of Pediatric Rheumatology. 5th ed. ed. Philadelphia: Elsevier Saunders; 2005. p. 206–303.CrossRefGoogle Scholar
  10. 10.
    Harrington J. Developmental issues in adolescence and the impact of rheumatic disease. In: Isenberg DA, Miller JJ, editors. Adolescent Rheumatology. London: Martin Dunitz; 2000. p. 21–34.Google Scholar
  11. 11.
    Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Pattern of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996;39:1703–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol. 1994;96:260–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Fink CW. Proposal for the development of classification criteria for the idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566–9.PubMedGoogle Scholar
  14. 14.
    Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.PubMedGoogle Scholar

Copyright information

© Japan College of Rheumatology 2012

Authors and Affiliations

  • Shumpei Yokota
    • 1
    Email author
  • Tomoyuki Imagawa
    • 1
  • Takuji Murata
    • 2
  • Minako Tomiita
    • 3
  • Yasuhiko Itoh
    • 4
  • Satoshi Fujikawa
    • 5
  • Syuji Takei
    • 6
  • Masaaki Mori
    • 7
  1. 1.Department of PediatricsYokohama City UniversityYokohamaJapan
  2. 2.Department of PediatricsOsaka Medical CollegeOsakaJapan
  3. 3.Department of PediatricsGraduate School of Medicine, Chiba UniversityChibaJapan
  4. 4.Department of PediatricsNippon Medical SchoolTokyoJapan
  5. 5.Institute of RheumatologyTokyo Women’s Medical UniversityTokyoJapan
  6. 6.School of Health Sciences, Faculty of Medicine, Kagoshima UniversityKagoshimaJapan
  7. 7.Department of PediatricsYokohama City University Medical CenterYokohamaJapan

Personalised recommendations